Business Description
Purple Biotech Ltd
ISIN : US74638P2083
Share Class Description:
PPBT: ADRTotal Employee Number:
10Compare
Compare
Traded in other countries / regions
PPBT.IsraelPPBT.USA1YI0.Germany IPO Date
2015-11-20Description
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 34.95 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 38.7 | |||||
3-Year EPS without NRI Growth Rate | 85.4 | |||||
3-Year FCF Growth Rate | 60.6 | |||||
3-Year Book Growth Rate | -72.9 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 27.27 | |||||
9-Day RSI | 26.96 | |||||
14-Day RSI | 28.29 | |||||
3-1 Month Momentum % | -27.32 | |||||
6-1 Month Momentum % | -58.91 | |||||
12-1 Month Momentum % | -87.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.48 | |||||
Quick Ratio | 1.48 | |||||
Cash Ratio | 1.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -115.9 | |||||
Shareholder Yield % | -46.55 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -111.33 | |||||
ROA % | -92.25 | |||||
ROIC % | -35.1 | |||||
3-Year ROIIC % | -163.73 | |||||
ROC (Joel Greenblatt) % | -8524.83 | |||||
ROCE % | -110.76 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.67 | |||||
EV-to-Forward-Revenue | 1.7 | |||||
EV-to-FCF | 0.01 | |||||
FCF Yield % | -108.07 |
GF Valueâ„¢
Purple Biotech Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Purple Biotech Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 137 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 38 days | ||
| General meeting for 2026 | 2026-06-26 16:30 | 1.75 (+0.57%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 3.69 (-6.95%) | ||
| Annual report for 2025 | 2026-03-19 | 3.81 (-4.75%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-13 | 3.84 (-4.00%) | ||
| 0.1:1 Stock Split | 2026-03-02 | 4.42 (-7.83%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 7.40 (-3.87%) | ||
| Second quarter earnings results for 2025 | 2025-08-06 | 22.60 (+3.43%) | ||
| First quarter earnings results for 2025 | 2025-05-21 | 24.10 (+4.78%) |
Show
Entries
Guru Commentaries on NAS:PPBT
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| TyrNovo to Present at 2018 Annual Meeting of the American Association for Cancer Research | 2018-04-13 |
Articles on Purple Biotech Ltd
No articles.